Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy

By sjmartinez • September 19, 2024

Rovin BH, Ronco PM, Wetzels JFM, Adler SG, Ayoub I, Zaoui P, Han SH, Dudani JS, Gilbert HN, Patel UD, Manser PT, Jauch-Lembach J, Faulhaber N, Boxhammer R, Härtle S, Sprangers B. Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy. Kidney Int Rep. 2024 Jun 20;9(9):2635-2647. doi: 10.1016/j.ekir.2024.06.018. PMID: 39291206; PMCID: PMC11403052.

Tags: Clinical Trial, felzartamab, Harbor UCLA, MOR202, Nephrology, phase 2, phospholipase A2 receptor, primary membranous nephropathy, Publications

Experiences and perspectives of patients and their caregivers on gastrointestinal symptoms in peritoneal dialysis: Workshop report

Hayat A, Johnson DW, Manera K, Viecelli AK, Wilkie M, Shen J, Wang AY, Htay H, Jaure A, Cho Y, Walker R. Experiences and perspectives[...]

Diabetes and longitudinal changes in deep learning-derived measures of vertebral bone mineral density using conventional CT: the Multi-Ethnic Study of Atherosclerosis

Ghotbi E, Hadidchi R, Hathaway QA, Bancks MP, Bluemke DA, Barr RG, Smith BM, Post WS, Budoff M, Lima JAC, Demehri S. Diabetes and longitudinal[...]

Obstructive Coronary Artery Disease Improved Prediction by the COME-CCT Pretest Probability Calculator With Cardiac CT

Wieske V, Walther M, Mohamed M, Weickert B, Andrzejewski S, Dubourg B, Andreini D, Pontone G, Alkadhi H, Hausleiter J, Garcia MJ, Leschka S, Meijboom[...]